美迪西(688202.SH)業績快報：2021年度淨利潤升117.93%至2.82億元
格隆匯2月25日丨美迪西(688202.SH)發佈2021年度業績快報，實現營業總收入11.67億元，同比增長75.27%；歸屬於母公司所有者的淨利潤2.82億元，同比增長117.93%；歸屬於母公司所有者的扣除非經常性損益的淨利潤2.71億元，同比增長119.29%；基本每股收益4.55元。
報吿期內，公司通過不斷優化經營效率，積極推進新實驗室建設，實驗室產能持續提升，規模效應得以進一步顯現，2021年度公司綜合毛利率為45.34%，較上年同期綜合毛利率41.07%增長4.27個百分點，2021年度公司淨利率為24.37%，較上年同期淨利率20.15%增長4.22個百分點。
報吿期內，受益於國家對醫藥產業政策鼓勵力度的不斷加大，以及製藥企業對創新藥物研發投入的持續提升，公司在優化業務結構的同時，緊緊把握臨牀前CRO市場的發展機遇，客户開拓能力和訂單承接能力同步提升。同時，公司不斷加強技術平台和人才隊伍建設，夯實臨牀前一體化綜合研發服務能力，並且在業務規模擴大的同時，積極推進各項提質增效措施，提升運營效率和盈利能力。
報吿期內，公司季度營業收入環比持續穩步增長，全年同比增長75.27%。主要系客户和市場對公司研發服務能力的認可度持續提升，充足的訂單為業績增長提供保障，2021年度公司新簽訂單24.52億元，新簽訂單增長率達87.66%。同時公司持續增強研發服務能力，為業績增長提供保障。2021年度公司持續推進和完善蛋白質降解技術(PROTAC)、激酶抑制劑的小分子藥物研發平台、放大生產工藝安全評價體系、難溶性創新藥口服固體制劑研發平台的建設，強化腫瘤免疫藥效評價、吸入及眼科藥物評價、核酸藥物評價、細胞治療產品及抗體等生物技術藥物的臨牀前安全性評價等技術平台建設，特別是在PROTAC平台、抗體等生物技術藥物的臨牀前安全性評價技術平台等方面加大資源投入，不斷增強公司的研發服務能力與競爭優勢。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
